Table 3 End-of-follow-up findings in Groups 1 and 2

Patients – n (%)

35 (56.4)

27 (43.6)

Duration (mo.) of PEGV therapy – median (range)

51 (15–72)

30 (6–72)*

Final weekly PEGV dose (mg) – median (range)

105 (70–210)

140 (70–280)

Final daily PEGV dose (mg)

10 mg – n (%)

10 (28.6)

11(40.7)

15 mg – n (%)

11 (31.4)

2 (7.4)

20 mg – n (%)

9 (25.7)

8 (29.6)

25 mg – n (%)

1 (2.8)

1 (3.7)

30 mg – n (%)

4 (11.4)

4 (14.8)

40 mg – n (%)

0 (0)

1 (3.7)

Group mean (±SD)

16.8 (±6.3)

17.9 (±8.4)

Group median (range)

15 (10–30)

20 (10–40)

Subgroup with IGF-I normalization at end of follow-up

15 (10–30)

10 (10–30)

Subgroup with abnormal IGF-I levels at end of follow-up

15 (10–20)

20 (10–40)*^#

Pts. requiring dose reduction during follow-up ^a – n (%)

5 (14.3)

4 (14.8)

Pts. with IGF-I normalization at any time during follow-up ^b – n (%)

29 (82.8)

18 (66.7)

Pts. with IGF-I normalization at end of follow-up – n (%)

28 (80)

15 (55.5)*

Final IGF-I levels

μg/L,Median (range)

212 (110–1216)^#

291 (150–1015)*^#

SDS (range)

1.0 (−0.5–14.1)^#

1.9 (−0.4–9.8)*^#

μg/L,Mean (±SD)

269 (± 203)

372 (± 216)*^#

Significant growth of (residual) adenoma - n (%)

0 (0)

1 (3.7)

Increase of liver enzymes - n (%)

5 (14.3)

3 (11.1)

Injections site events - n (%)

1 (2.9)

1 (3.7)